Actively Recruiting
Study to Assess the Effectiveness of Faricimab Injections for Treating Neovascular Age-related Macular Degeneration in Adults Aged 50 and Older
Led by Junyeop Lee · Updated on 2026-07-27
64
Participants Needed
5
Research Sites
35 weeks
Total Duration
AI-Summary
What This Trial Is About
This research evaluates the use of Faricimab in adults aged 50 years or older with neovascular age-related macular degeneration nAMD. The study is a Phase IV, open-label, single-arm trial investigating the efficacy of Faricimab and assessing biomarkers related to the disease. Participants must have active nAMD confirmed by retinal imaging and meet visual acuity requirements to participate. Participants will receive Faricimab injections 6 mg, 0.05 mL administered into the eye every 4 weeks for the first four doses during the loading phase. After this, disease activity will be assessed at Week 20 using imaging and vision tests to decide the next injection timing, which may be at Week 28 or Week 32. Subsequent dosing intervals will be adjusted in 4-week increments based on ongoing assessments. The total number of injections ranges from 7 to 9 over the study period. Throughout the study, participants will attend at least 10 visits, including screening, with visual acuity tests, retinal imaging, and biomarker assessments performed at specified weeks. Researchers will measure ANG-2 levels in eye fluid, visual acuity, retinal thickness, vessel density, and other eye health indicators to evaluate treatment impact. Safety and treatment intervals will be monitored until the study ends.
CONDITIONS
Brief Title
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
Research Team
J
Junyeop Lee, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here